Johnson & Johnson stock gains attention as $20 billion orthopedics sale talks emerge
Published on 09/13/2026 at 14:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson stock (ISIN US4781601046) is trading close to USD 266 on the New York Stock Exchange as of September 12, 2026, with investors focused on potential divestment of its orthopedics business valued at about USD 20 billion. As of September 12, 2026, several data providers place the company’s market capitalization at around USD 640.0 billion, underlining the scale of the healthcare group.
Orthopedics sale talks reshape Johnson & Johnson’s portfolio
According to Wall Street Journal on September 12, 2026, Johnson & Johnson is in talks to sell its hips-and-knees DePuy Synthes business to Apollo Global Management for about USD 20 billion, signalling a major rebalancing of its medtech portfolio.
Further detail on the potential transaction is provided by GuruFocus, which reports on September 13, 2026 that negotiations concern the DePuy Synthes orthopedic division, with a deal value around USD 20 billion and room for other bidders to enter the process.
As Simply Wall St notes in coverage dated September 12, 2026, Johnson & Johnson is weighing a broader medtech shift by considering the exit from DePuy Synthes, positioning the company to concentrate on higher-growth medical technology areas.
Stock valuation, dividend and financial metrics
GuruFocus calculates a GF Value of USD 193.26 for Johnson & Johnson compared with a current share price of USD 265.58 as of September 11, 2026, implying the stock trades about 37.4 percent above this intrinsic value estimate.
The same analysis reports a trailing twelve month price-to-earnings ratio of 30.77 times for Johnson & Johnson versus a five-year median P/E of 23.77 times, indicating the shares trade at a premium to the company’s recent valuation history as of the latest data in September 2026.
According to dividend data from StockAnalysis updated on September 11, 2026, Johnson & Johnson pays an annual dividend of USD 5.36 per share, corresponding to a dividend yield of about 2.02 percent at a closing price of USD 265.58.
StockAnalysis also shows that Johnson & Johnson shares closed at USD 265.58 on the New York Stock Exchange on September 11, 2026, down 0.29 percent for that session, with an after-hours indication of USD 265.99, up 0.15 percent later on the same date.
Market capitalization figures compiled by CompaniesMarketCap as of September 12, 2026, show Johnson & Johnson with a market value of USD 640.02 billion, which aligns with Nasdaq-based data cited for the same date.
Analyst views and recent institutional activity
According to an analyst note summarized by The Globe and Mail on September 12, 2026, DBS maintained a Hold rating on Johnson & Johnson stock with a price target of USD 270.00, while a broader analyst consensus compiled in the same report points to an average target of about USD 286.61 and a consensus stance of Strong Buy.
In addition, institutional trading activity continues around the name. As MarketBeat reported on September 13, 2026, TD Waterhouse Canada Inc. acquired 29,365 Johnson & Johnson shares, with JNJ stock opening that day at USD 265.91.
A second institutional update from MarketBeat on September 13, 2026 notes executive share transactions around an average sale price of USD 263.36, and it cites MarketBeat data showing a consensus rating of Moderate Buy with an average price target of about USD 274.13.
Stock price levels, range and investor perspective
Trading data compiled by Robinhood for Johnson & Johnson indicate a current share price of USD 266.20 as of the session dated September 12, 2026, with the same session seeing a high of USD 270.39 and a low of USD 265.25, leaving the stock about 1.5 percent below that intraday high at the reference price of USD 266.20.
The Robinhood overview also shows Johnson & Johnson with a market capitalization of about USD 640.12 billion at that price, broadly in line with separate market cap figures from CompaniesMarketCap for September 12, 2026.
Recent commentary from Kalkine Media on September 13, 2026 notes that Johnson & Johnson is reshaping its medical-device portfolio, linking the DePuy Synthes sale talks to a broader medtech repositioning while citing a share price level of USD 265.58.
From an investor perspective, the combination of a roughly 2.0 percent dividend yield, a premium valuation versus historical P/E levels and a potential USD 20 billion portfolio transaction creates a mixed picture: the stock offers steady income and strong financial metrics, but valuation indicators such as the GF Value signal that Johnson & Johnson may be significantly overvalued at current prices relative to intrinsic estimates.
Johnson & Johnson stock price as of the last session
For reference, Johnson & Johnson stock closed at USD 265.58 on the New York Stock Exchange on September 11, 2026, with a modest daily decline of 0.29 percent and after-hours trading nudging the price to about USD 265.99 later that day; this closing level anchors the valuation metrics and yield figures mentioned above and sits slightly below the USD 266.20 price snapshot reported for September 12, 2026.
Johnson & Johnson stock at a glance
- Company: Johnson & Johnson
- ISIN: US4781601046
- Ticker: JNJ
- Trading venue: NYSE
- Price (as of September 11, 2026, 16:00): 265.58 USD
- Market capitalization: 640.02 billion USD (as of September 12, 2026)
- Sector / Industry: Healthcare / Pharmaceuticals and medical devices
- Index membership: S&P 500
